XNYS
PFE
Market cap158bUSD
Oct 08, Last price
27.82USD
1D
-0.64%
1Q
15.10%
Jan 2017
-9.72%
Name
Pfizer Inc
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of its offerings comprises vaccines for infectious diseases such as pneumococcal and meningococcal disease, tick-borne encephalitis, and COVID-19, with notable products like Comirnaty and the Prevnar family. The firm also develops biosimilars for chronic autoimmune and inflammatory disorders, including Inflectra and Xeljanz, alongside specialized therapies for rare conditions like amyloidosis, hemophilia, and endocrine disorders, under brands such as Vyndaqel and BeneFIX. Beyond its proprietary products, Pfizer operates a contract manufacturing division. Its extensive customer base includes wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual medical practices, and public health organizations. The company actively fosters strategic collaborations with numerous partners, such as Bristol-Myers Squibb Company, BioNTech SE, and Merck KGaA. Established in 1849, Pfizer Inc. is headquartered in New York, New York.
Related entities
Subsidiaries (146)
AHP Manufacturing B.V.
C.P. Pharmaceuticals International C.V.
JOHN WYETH & BROTHER LIMITED
PF PRISM HOLDINGS B.V.
PF PRISM IMB B.V.
Pfizer
Pfizer Aktiebolag
Pfizer Anti-Infectives AB
PFIZER ASIA MANUFACTURING COOP UA
PFIZER CONSUMER HEALTHCARE
PFIZER CORK LIMITED
PFIZER DEVELOPMENT SERVICES (UK) LIMITED
Pfizer Global Holdings B.V.
PFIZER GROUP LUXEMBOURG S.A R.L.
PFIZER H.C.P. CORPORATION
Pfizer Health AB
PFIZER HEALTHCARE IRELAND UNLIMITED COMPANY
PFIZER HOLDING FRANCE
PFIZER INVESTMENT ENTERPRISES PTE. LTD.
PFIZER IRELAND PHARMACEUTICALS UNLIMITED COMPANY
Key people
Albert Bourla
Chairman of the Board, Chief Executive Officer · since 2020
Executive Vice President, Chief Financial Officer · since 2022
Alexandre De Germay
Executive Vice President, Chief International Commercial Officer · since 2023
Executive Vice President, Chief Digital and Technology Officer · since 2019
Douglas Lankler
Executive Vice President, Chief Legal Officer · since 2025
Aamir Malik
Executive Vice President, Chief US Commercial Officer · since 2023
Michael Mcdermott
Executive Vice President, Chief Global Supply Officer · since 2022
Payal Sahni
Executive Vice President, Chief People Experience Officer · since 2022
Executive Vice President, Chief Corporate Affairs Officer · since 2019
Chris Boshoff
Chief Scientific Officer, President - Research & Development · since 2025
Lead Independent Director · since 2019
Ronald Blaylock
Independent Director · since 2017
Independent Director · since 2024
Susan Desmond-Hellmann
Independent Director · since 2020
Independent Director · since 2015
Independent Director · since 2019
Independent Director · since 2020
Suzanne Johnson
Independent Director · since 2007
Dan Littman
Independent Director · since 2018
Independent Director · since 2020
Legal address
C/O THE CORPORATION TRUST COMPANY
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
CORPORATION TRUST CENTER
1209 ORANGE ST
WILMINGTON, DE 19801
US
Headquarters
235 EAST 42ND STREET
NEW YORK, NY 10017
US
NEW YORK, NY 10017
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||